Minassian DC, Owens DR, Reidy A. Prevalence of diabetic macular oedema and related health and social care resource use in England. Br J Ophthalmol. 2012;96:345–9.

Article  CAS  PubMed  Google Scholar 

Romero-Aroca P. Managing diabetic macular edema: the leading cause of diabetes blindness. World J Diabetes. 2011;2:98.

Article  PubMed  PubMed Central  Google Scholar 

Haider S, Thayakaran R, Subramanian A, Toulis KA, Moore D, Price MJ, et al. Disease burden of diabetes, diabetic retinopathy and their future projections in the UK: cross-sectional analyses of a primary care database. BMJ Open. 2021;11:e050058.

Article  PubMed  PubMed Central  Google Scholar 

NHS Digital. National Diabetes Audit Programme. 2022. https://digital.nhs.uk/data-and-information/clinical-audits-and-registries/national-diabetes-audit.

Lakdawalla DN, Doshi JA, Garrison LP,Jr, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care—a health economics approach: an ISPOR special task force report [3]. Value Health. 2018;21:131–9.

Article  PubMed  Google Scholar 

Neumann PJ, Garrison LP, Willke RJ. The history and future of the “ISPOR Value Flower”: addressing limitations of conventional cost-effectiveness analysis. Value Health. 2022;25:558–65.

Article  PubMed  Google Scholar 

McCartney G, Popham F, McMaster R, Cumbers A. Defining health and health inequalities. Public Health. 2019;172:22–30.

Article  CAS  PubMed  Google Scholar 

NICE. NICE strategy 2021 to 2026. London: National Institute for Health and Care Excellence; 2021.

NHS Digital. Data on file: quality and outcomes framework, 2021–22. 2022. https://digital.nhs.uk/data-and-information/publications/statistical/quality-and-outcomes-framework-achievement-prevalence-and-exceptions-data/2021-22.

Connolly V, Unwin N, Sherriff P, Bilous R, Kelly W. Diabetes prevalence and socioeconomic status: a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. J Epidemiol Community Health. 2000;54:173–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hippisley-Cox J, Coupland C, Robson J, Sheikh A, Brindle P. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ. 2009;338:b880.

Article  PubMed  PubMed Central  Google Scholar 

Mathur R, Farmer RE, Eastwood SV, Chaturvedi N, Douglas I, Smeeth L. Ethnic disparities in initiation and intensification of diabetes treatment in adults with type 2 diabetes in the UK, 1990–2017: a cohort study. PLoS Med. 2020;17:e1003106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pham TM, Carpenter JR, Morris TP, Sharma M, Petersen I. Ethnic differences in the prevalence of type 2 diabetes diagnoses in the UK: cross-sectional analysis of the health improvement network primary care database. Clin Epidemiol. 2019;11:1081–8.

Gov.UK. Ethnicity facts and figures: people living in deprived neighbourhoods. 2020. https://www.ethnicity-facts-figures.service.gov.uk/uk-population-by-ethnicity/demographics/people-living-in-deprived-neighbourhoods/latest#full-page-history.

NHS Digital. National Diabetes Audit 2021–22, report 1: care processes and treatment targets, detailed analysis report. 2023. https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-1-care-processes-and-treatment-targets-2021-22-full-report/health-ineq-1718-2122.

Whyte MB, Hinton W, McGovern A, van Vlymen J, Ferreira F, Calderara S, et al. Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: a retrospective cohort analysis. PLoS Med. 2019;16:e1002942.

Article  PubMed  PubMed Central  Google Scholar 

Boye KS, Thieu VT, Lage MJ, Miller H, Paczkowski R. The association between sustained HbA1c control and long-term complications among individuals with type 2 diabetes: a retrospective study. Adv Ther. 2022;39:2208–21.

Article  PubMed  PubMed Central  Google Scholar 

Wild SH, McKnight JA, McConnachie A, Lindsay RS. Socioeconomic status and diabetes-related hospital admissions: a cross-sectional study of people with diagnosed diabetes. J Epidemiol Community Health. 2010;64:1022–4.

Article  PubMed  Google Scholar 

Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022;18:525–39.

Article  PubMed  PubMed Central  Google Scholar 

Heath Jeffery RC, Mukhtar SA, McAllister IL, Morgan WH, Mackey DA, Chen FK. Inherited retinal diseases are the most common cause of blindness in the working-age population in Australia. Ophthalmic Genet. 2021;42:431–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. BMJ Open. 2014;4:e004015.

Article  PubMed  PubMed Central  Google Scholar 

Low L, Law JP, Hodson J, McAlpine R, O’Colmain U, MacEwen C. Impact of socioeconomic deprivation on the development of diabetic retinopathy: a population-based, cross-sectional and longitudinal study over 12 years. BMJ Open. 2015;5:e007290.

Article  PubMed  PubMed Central  Google Scholar 

Denniston AK, Lee AY, Lee CS, Crabb DP, Bailey C, Lip PL, et al. United Kingdom Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group: report 4, real-world data on the impact of deprivation on the presentation of diabetic eye disease at hospital services. Br J Ophthalmol. 2019;103:837–43.

Article  PubMed  Google Scholar 

Gov.UK. Diabetic eye screening: programme overview. 2014. https://www.gov.uk/guidance/diabetic-eye-screening-programme-overview.

Gov.UK. NHS screening programmes in England: 2019 to 2020. 2023. https://www.gov.uk/government/publications/nhs-screening-programmes-annual-report/nhs-screening-programmes-in-england-2019-to-2020#nhs-diabetic-eye-screening-des-programme.

Gov.UK. NHS screening programmes in England: 2020 to 2021. 2023. https://www.gov.uk/government/publications/nhs-screening-programmes-annual-report/nhs-screening-programmes-in-england-2020-to-2021.

Scanlon PH. The contribution of the English NHS Diabetic Eye Screening Programme to reductions in diabetes-related blindness, comparisons within Europe, and future challenges. Acta Diabetol. 2021;58:521–30.

Article  PubMed  PubMed Central  Google Scholar 

Waqar S, Bullen G, Chant S, Salman R, Vaidya B, Ling R. Cost implications, deprivation and geodemographic segmentation analysis of non-attenders (DNA) in an established diabetic retinopathy screening programme. Diabet Metab Syndr. 2012;6:199–202.

Article  Google Scholar 

Thomas RL, Cheung WY, Rafferty JM, Luzio SD, Akbari A, Owens DR. Characteristics of repeat non‐attenders at Diabetes Eye Screening Wales, a national community‐based diabetes‐related retinopathy screening service, during 2003–2018. Diabet Med. 2021;38:e14536.

Article  PubMed  Google Scholar 

Olvera-Barrios A, Seltene M, Heeren TF, Chambers R, Bolter L, Tufail A, et al. Effect of ethnicity and other sociodemographic factors on attendance at diabetic eye screening: a 12-month retrospective cohort study. BMJ Open. 2021;11:e046264.

Article  PubMed  PubMed Central  Google Scholar 

Gale R, Scanlon PH, Evans M, Ghanchi F, Yang Y, Silvestri G, et al. Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. Eye. 2017;31:S1–S20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Virgili G, Parravano M, Evans J, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor (anti-VEGF) drugs for diabetic macular oedema: a network meta‐analysis. Cochrane Database Syst Rev. 2017;6:CD007419.

PubMed  Google Scholar 

Talks S, Stratton I, Peto T, Lotery A, Chakravarthy U, Eleftheriadis H, et al. Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years. Eye. 2022;36:72–7.

Article  CAS  PubMed  Google Scholar 

Peto T, Akerele T, Sagkriotis A, Zappacosta S, Clemens A, Chakravarthy U. Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: a real‐world study. Diabet Med. 2022;39:e14746.

Article  CAS  PubMed  Google Scholar 

Alvarez-Ramos P, Jimenez-Carmona S, Alemany-Marquez P, Cordoba-Doña JA, Aguilar-Diosdado M. Socioeconomic deprivation and development of diabetic retinopathy in patients with type 1 diabetes mellitus. BMJ Open Diabetes Res Care. 2020;8:e001387.

Article  PubMed  PubMed Central  Google Scholar 

Nguyen CTN, Yosef M, Khalatbari S, Shah AR. Sociodemographic variables associated with risk for diabetic retinopathy. Clin Diabetes Endocrinol. 2022;8:7.

Article  PubMed  PubMed Central  Google Scholar 

Patel D, Ananthakrishnan A, Lin T, Channa R, Liu TA, Wolf RM. Social determinants of health and impact on screening, prevalence, and management of diabetic retinopathy in adults: a narrative review. J Clin Med. 2022;11:7120.

Article  CAS  PubMed  PubMed Central  Google Scholar 

NHS Digital. Data on file. Hospital outpatient activity 2019–20: all attendances. 2020. https://digital.nhs.uk/data-and-information/publications/statistical/hospital-outpatient-activity/2019-20.

Hollingworth W, Jones T, Reeves BC, Peto T. A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015. BMJ Open. 2017;7:e018289.

Article  PubMed  PubMed Central  Google Scholar 

Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741–55.

Article  CAS  PubMed  Google Scholar 

NICE. Supporting the health and care system in improving productivity. 2023. https://www.nice.org.uk/productivity.

Asaria M, Griffin S, Cookson R. Distributional cost-effectiveness analysis: a tutorial. Med Decis Making. 2016;36:8–19.

Article  PubMed  Google Scholar 

Love-Koh J, Cookson R, Gutacker N, Patton T, Griffin S. Aggregate distributional cost-effectiveness analysis of health technologies. Value Health. 2019;22:518–26.